Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.80 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.80 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834781 | 1.00 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL6368120 | 1.00 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL13834782 | 1.00 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL27505531 | 1.00 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL8091045 | 1.00 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL27888191 | 1.00 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL26927585 | 1.00 | P2RY6 (0.81) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL2056922 | 0.99 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL4071893 | 0.99 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL157645 | 0.99 | P2RY6 (0.83) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290505-A | Intelligent control crystallization method and crystallization system for 5' -uridylic acid sodium salt | 上海蔚之星生物科技有限公司 | 2024-07-05 | — | — | CN | claimed |
| EP-2734060-A1 | USE OF A NUCLEOTIDE FOR IMPROVING THE HEAT STABILITY OF AN AQUEOUS MICELLAR CASEIN COMPOSITION | N.V. Nutricia (NL) | 2014-05-28 | — | — | EP | claimed |
| WO-2013012324-A1 | USE OF A NUCLEOTIDE FOR IMPROVING THE HEAT STABILITY OF AN AQUEOUS MICELLAR CASEIN COMPOSITION | N.V. NUTRICIA (NL) | 2013-01-24 | — | — | WO | claimed |
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | FERRER INTERNACIONAL, S.A. (ES) | 2026-01-27 | — | — | US | disclosed |
| CN-118290505-A | Intelligent control crystallization method and crystallization system for 5' -uridylic acid sodium salt | 上海蔚之星生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118290505-A | Intelligent control crystallization method and crystallization system for 5' -uridylic acid sodium salt | 上海蔚之星生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118290505-A | Intelligent control crystallization method and crystallization system for 5' -uridylic acid sodium salt | 上海蔚之星生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220160744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | FERRER INTERNACIONAL, S.A. (ES) | 2022-05-26 | — | — | US | disclosed |
| EP-3965744-A1 | MULTILAYER PHARMACEUTICAL OR NUTRACEUTICAL SOLID DOSAGE FORMS COMPRISING PYRIMIDINE AND/OR PURINE DERIVATIVES AND B VITAMINS, PREPARATION AND USES THEREOF | Ferrer Internacional, S.A. (ES) | 2022-03-16 | — | — | EP | disclosed |
| WO-2021150501-A1 | EXPANDED FOAM FOR DELIVERY OF FUNCTIONAL INGREDIENTS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20210154122-A1 | TOPICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-6316426-B1 | NUCLEOSIDE DERIVATIVE FOR DIABETES, HEART DISEASE, CEREBROVASCULAR DISORDERS, PARKINSON'S DISEASE, INFANT RESPIRATORY DISTRESS SYNDROME AND FOR ENHANCEMENT OF PHOSPHOLIPID BIOSYNTHESIS | PRO-NEURON, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6274563-B1 | ADMINISTERING AS ANTIDIABETIC AGENT | PRO-NEURON, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6258795-B1 | Acylated uridine and cytidine and uses thereof | PRO-NEURON, INC. | 2001-07-10 | — | — | US | disclosed |
| US-5583117-A | CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS; DIABETES | PRO-NEURON, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5470838-A | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine | PRO-NEURON, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0339075-B1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533371-B2 | Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof | P2RY10, TYMP, P2RY12 | P2RY6 17/4885P2RY2 42/4885P2RY4 37/4885 |
| US-20210154122-A1 | TOPICAL COMPOSITION | UNG, UPP1, RNGTT | P2RY6 755/4885P2RY2 1070/4885P2RY4 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.